Overall CHF supports the recommended priorities and actions and welcomes the commitment to further consultation with children, families and young people as implementation plans are developed and operationalised. We welcome ARACY’s proposed life course approach: it is important that the plan...
Response to the Report from the General Practice and Primary Care Clinical Committee: Phase 2
CHF supports the changes that the GPPCCC have been made in their Phase 2 Report and feel that their vision of the health system aligns closely with what we hear from members. We are pleased that...
Response to the Report from the General Practice and Primary Care Clinical Committee: Phase 2
CHF supports the changes that the GPPCCC have been made in their Phase 2 Report and feel that their vision of the health system aligns closely with what we hear from members. We are pleased that...
CHF appreciates the opportunity to provide a comment to the Therapeutic Goods Administration (TGA) proposal to introduce a Unique Device Identification (UDI) system for medical devices in Australia.
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s...
The CHF supports the reintroduction of pills into the scope of the remade Order. The omission of these from the current Order is an unfortunate regulatory oversight. Consumers implicitly trust the regulatory system to ensure any product made available to them undergoes rigorous assessment of...
We expect the primary impact of the reclassification for consumers will be a greater level of quality for Active Medical Devices in terms of reliability, safety and effectiveness. By putting these medical devices into a higher class they will undergo more rigorous assessment prior to becoming...
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation has been formed with a patient-centred approach in mind. CHF notes that this consultation’s scope is limited to the regulatory guidance in line with existing regulatory requirements, and not...
CHF appreciates the opportunity to provide a comment in response to proposed changes to a number of definitions and the scope of the medical device regulatory framework in Australia. At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation...
Subscribe to our newsletter 'Consumers Shaping Health' to keep up to date with what we're doing and how you can best make your voice heard. You can also elect to hear from us on upcoming opportunities and events.
